The described invention provides a method for reducing visual loss and for treating one or more of adverse consequence of an eye disease, including abnormal intraocular pressure, retinal vascular disease, retinal ganglion cell death, or a combination thereof in order to reduce visual loss. The method entails providing a flowable particulate composition that contains a particulate formulation comprising a plurality of particles of uniform size distribution, a therapeutic amount of a therapeutic agent selected from a voltage-gated calcium channel antagonist, an endothelin receptor antagonist, or a combination thereof, and optionally an additional therapeutic agent, wherein the particles are of uniform size distribution, and wherein each particle comprises a matrix； and a pharmaceutically acceptable carrier.
